Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Yale Stem Cell Center, Department of Genetics, Yale School of Medicine, Yale University, New Haven, CT, United States.
Biotechnol Adv. 2018 Jan-Feb;36(1):132-149. doi: 10.1016/j.biotechadv.2017.10.005. Epub 2017 Oct 19.
Organoids are in vitro cultures of miniature fetal or adult organ-like structures. Their potentials for use in tissue and organ replacement, disease modeling, toxicology studies, and drug discovery are tremendous. Currently, major challenges facing human organoid technology include (i) improving the range of cellular heterogeneity for a particular organoid system, (ii) mimicking the native micro- and matrix-environment encountered by cells within organoids, and (iii) developing robust protocols for the in vitro maturation of organoids that remain mostly fetal-like in cultures. To tackle these challenges, we advocate the principle of reverse engineering that replicates the inner workings of in vivo systems with the goal of achieving functionality and maturation of the resulting organoid structures with the input of minimal intrinsic (cellular) and environmental (matrix and niche) constituents. Here, we present an overview of organoid technology development in several systems that employ cell materials derived from fetal and adult tissues and pluripotent stem cell cultures. We focus on key studies that exploit the self-organizing property of embryonic progenitors and the role of designer matrices and cell-free scaffolds in assisting organoid formation. We further explore the relationship between adult stem cells, niche factors, and other current developments that aim to enhance robust organoid maturation. From these works, we propose a standardized pipeline for the development of future protocols that would help generate more physiologically relevant human organoids for various biomedical applications.
类器官是体外培养的微型胎儿或成人器官样结构。它们在组织和器官替代、疾病建模、毒理学研究和药物发现方面具有巨大的潜力。目前,人类类器官技术面临的主要挑战包括:(i)提高特定类器官系统的细胞异质性范围;(ii)模拟细胞在类器官内遇到的天然微环境和基质环境;(iii)开发用于体外成熟类器官的稳健方案,这些类器官在培养中仍然主要具有胎儿样特征。为了解决这些挑战,我们提倡逆向工程的原则,即用该原则复制体内系统的内部工作原理,目的是实现所得到的类器官结构的功能和成熟,而输入的最小内在(细胞)和环境(基质和生态位)成分。在这里,我们概述了几种系统中类器官技术的发展,这些系统使用源自胎儿和成人组织以及多能干细胞培养物的细胞材料。我们重点介绍了利用胚胎祖细胞的自组织特性以及设计基质和无细胞支架在协助类器官形成中的作用的关键研究。我们进一步探讨了成年干细胞、生态位因素以及其他旨在增强稳健类器官成熟的当前发展之间的关系。从这些工作中,我们提出了一个未来方案的标准化管道,这将有助于为各种生物医学应用生成更具生理相关性的人类类器官。